Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.
Eur Heart J. 2022 Apr 6;43(14):1401-1412. doi: 10.1093/eurheartj/ehab820.
Eur Heart J. 2022.
PMID: 35025993
Free PMC article.
Clinical Trial.
Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia.
Karwatowska-Prokopczuk E, Tardif JC, Gaudet D, Ballantyne CM, Shapiro MD, Moriarty PM, Baum SJ, Amour ES, Alexander VJ, Xia S, Otvos JD, Witztum JL, Tsimikas S; Olezarsen Trial Investigators.
Karwatowska-Prokopczuk E, et al. Among authors: amour es.
J Clin Lipidol. 2022 Sep-Oct;16(5):617-625. doi: 10.1016/j.jacl.2022.06.005. Epub 2022 Jun 23.
J Clin Lipidol. 2022.
PMID: 35902351
Free article.
Item in Clipboard
Management of High Hepatopulmonary Shunts in the Setting of Y90 Radioembolization.
Schiro BJ, Amour ES, Harnain C, Gandhi RT.
Schiro BJ, et al. Among authors: amour es.
Tech Vasc Interv Radiol. 2019 Jun;22(2):58-62. doi: 10.1053/j.tvir.2019.02.004. Epub 2019 Feb 27.
Tech Vasc Interv Radiol. 2019.
PMID: 31079711
Item in Clipboard
Cite
Cite